NewsfeedFollowed Companies

BDSI's Competitors, Revenue, Number of Employees, Funding and Acquisitions

BioDelivery is a pharmaceutical company that primarily focuses on developing medicines for pain management and addiction... Read more

Based on data from BDSI's latest SEC filings

Annual Revenue

Based on data from BDSI's latest SEC filings

Employees

Herm Cukier's photo - CEO of BDSI

CEO

Herm Cukier

CEO Approval Rating

84/100

OVERVIEW

Founded:

1997

Headquarters:

RaleighNorth Carolina

Status:

PublicIndependent Company of NASDAQBDSI

Industry Sector:

- -

SIC Code:

8000NAICS listing »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Spinifex a competitor of BDSI?

I don't know

Trending News for BDSI and BDSI's Competitors

January 17, 2020

BioSpace

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2019 Financial Results Conference Call

NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2019 fourth quarter and fu... See more »

Competitive Analysis

TOP COMPETITORS OR ALTERNATIVES

Flexion Therapeutics is seen as one of BDSI's biggest rivals. Flexion Therapeutics is headquartered in Burlington, Massachusetts, and was founded in 2007. Flexion Therapeutics competes in the Pharmaceuticals field. Flexion Therapeutics generates 60% the revenue of BDSI.

Zogenix is seen as one of BDSI's top competitors. Zogenix was founded in 2006, and its headquarters is in San Diego, California. Zogenix operates in the Pharmaceuticals industry. Zogenix has 9 fewer employees than BDSI.

Ethypharm is one of BDSI's top rivals. Ethypharm is a Private company that was founded in Saint-Cloud Cedex, Île-de-France in 1977. Ethypharm competes in the Health Care Technology industry. Ethypharm has 851 more employees vs. BDSI.

RANK

COMPANY

LEADERSHIP

CEO SCORE

EMPLOYEES

TOTAL FUNDING

REVENUE

Herm Cukier

CEO

- -
99
$105.5M
$97.8M
1

Mike Clayman

Co-Founder & CEO

83/100
95
$190M
$58.8M
2

Stephen J. Farr

President & CEO

79/100
67
$264.3M
$1.7M
3

Bertrand Deluard

CEO

81/100
950
- -
$15M
4

Conrad F Mir

President & CEO

79/100
7
$550.1K
$1.2M
5

Tom McCarthy

President & CEO

66/100
30
$66.5M
6

Stephen J. D’Amato

Founder

68/100
20
- -
$4.4M
7

Paul V. Campanelli

Chairman & CEO

72/100
6,406
$5.7M
$2.9B
8

Vincent J. Angotti

CEO

69/100
214
$72.5M
$48.2M
9

Gabriel Baertschi

Chairman & CEO

80/100
5,300
- -
$1.7B
10

Bernard D. King

CEO

86/100
6
$65M
$4M
The top 10 competitors in BDSI's competitive set are Flexion Therapeutics, Zogenix, Ethypharm, Calmare, Spinifex, Calmar Pain Relief, Endo Pharmaceuticals, XenoPort, Grunenthal and Thesan. Together they have raised over 664.5M between their estimated 9.8K employees. BDSI has 99 employees and is ranked 5th among it's top 10 competitors. The top 10 competitors average 1,199.

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$97.8M

BDSI's revenue is the ranked 3rd among it's top 10 competitors. The top 10 competitors average 487.1M. Over the last three quarters, BDSI's revenue has grown by 53.3%. Specifically, in Q3 2019's revenue was $30.3M; in Q2 2019, it was $29.7M; in Q1 2019, it was $19.8M.

Acquisitions

No recent acquisitions found related to BDSI

BDSI Funding History

Since BDSI was founded in 1997, it has participated in 5 rounds of funding. In total BDSI has raised $105.5M. BDSI's last funding round was on May 2018 for a total of $50.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
May 2018
$50M

Broadfin Capital

Debt
Feb 2017
$45M
Unattributed
Oct 2009
$1.3M
Unattributed
Sep 2002
$600K
IPO
Jun 2002
$8.6M

Total Funding: $105.5M

Since BDSI was founded in 1997, it has participated in 5 rounds of funding. In total BDSI has raised $105.5M. BDSI's last funding round was on May 2018 for a total of $50.0M

Investments

No recent investments found related to BDSI

BDSI News

November 25, 2019Benzinga

BioDelivery Sciences Appoints Dr. Vanila Singh, Former Chief Medical Officer of Health and Human Services, to its Board of Directors

RALEIGH, N.C., Nov. 25, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDS... See more »
November 14, 2019Seeking Alpha

BioDelivery's Bountiful Growth

See more »
October 30, 2019BioSpace

BioDelivery Sciences to Report Third Quarter 2019 Financial Results and Host Conference Call on November 12, 2019

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company dedicated... See more »
October 18, 2019Zacks

Will Owens & Minor Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Owens & Minor.... See more »
September 17, 2019Seeking Alpha

Fundamentals And Chart Aligned - The Stock Should Continue To Run

See more »
September 12, 2019Law 360

Biopharma Co. Investors Allege Voting Rule Fouls In Del. Suit

BioDelivery Sciences International Inc. stockholders have sued the specialty pharmaceutical company a... See more »
August 29, 2019Benzinga

BioDelivery Sciences Announces Upcoming Investor Conference Presentations

RALEIGH, N.C., Aug. 29, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDS... See more »

BDSI Press Releases

October 1, 2019GlobeNewswire

BioDelivery Sciences Announces Significant Additional Insurance Coverage for both BELBUCA® and Symproic®

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company dedicated... See more »
June 24, 2019GlobeNewswire

BioDelivery Sciences Expands Upon Report from Pain Management Task Force

Company's Activities Support Buprenorphine Recommendations Including:... See more »
May 29, 2019GlobeNewswire

BioDelivery Sciences Announces Upcoming Investor Conference Presentations

RALEIGH, N.C., May 29, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDS... See more »
May 6, 2019GlobeNewswire

BioDelivery Sciences Reports Strong First Quarter 2019 Results and Raises BELBUCA® Full-Year Expectations

BELBUCA® Net Sales Increased by 134% versus Prior Year to All-time High of $18.7 MillionSymproic® Acq... See more »
April 25, 2019GlobeNewswire

BioDelivery Sciences to Report First Quarter 2019 Financial Results

RALEIGH, N.C., April 25, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: B... See more »
February 21, 2019GlobeNewswire

BioDelivery Sciences to Report Fourth Quarter and Full Year 2018 Financial Results

RALEIGH, N.C., Feb. 21, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BD... See more »
November 8, 2018StreetInsider

BioDelivery Sciences Reports Strong Third Quarter 2018 Financial Results

RALEIGH, N.C., Nov. 08, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BD... See more »

Social Statistics

Headquarters

4131 Parklake Avenue Suite 225

Raleigh, North Carolina27612

919-582-9050

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

BioDelivery is a pharmaceutical company that primarily focuses on developing medicines for pain management and addiction. BDSI was founded in 1997. BDSI's headquarters is located in Raleigh, North Carolina, USA 27612. It has raised 105.5M in 5 rounds....

CEO

BDSI's CEO, Herm Cukier, currently has an approval rating of 84%. BDSI's primary competitors are Flexion Therapeutics, Zogenix & Ethypharm.

Website

bdsi.com

Frequently Asked Questions about BDSI

  1. When was BDSI founded?

    BDSI was founded in 1997

  2. Who is BDSI's CEO?

    BDSI's CEO is Herm Cukier

  3. How much revenue does BDSI generate?

    BDSI generates $97.8M in revenue

  4. How much funding does BDSI have?

    BDSI has historically raised $105.5M in funding

  1. Where is BDSI's headquarters?

    BDSI's headquarters is in Raleigh North Carolina, USA

  2. How many employees does BDSI have?

    BDSI has 99 employees

  3. Who are BDSI's competitors?

    BDSI's top competitors are Flexion Therapeutics, Zogenix, Ethypharm
Stay up-to-date with the latest news on BDSI